2. Puma Biotechnology focus on the acquisition, development and commercialization of innovative
products to enhance cancer care.
Aim to acquire proprietary rights to these products, by license or otherwise, fund their research
and development and bring the products to market
License the rights to three drug candidates PB272 (neratinib (oral)), PB272 (neratinib
(intravenous)), PB357
Strategy is to become a leading oncology-focused biopharmaceutical company.
Phase 3 CompletionPhase 2Phase 1
DESCRIPTION
PIPELINE
DESCRIPTION SNAPSHOT
Source: COMPANY OVERVIEW
5 CATALYST
Profit & Loss 2010 2011 2012 2013 2014
Gross profit/loss 0 0 0 0 0
Operating Loss (15,976) (2,504) (54,820) (47,314) (103,124)
Net Loss (15,976) (2,580) (54,722) (47,140) (102,814)
Balance sheet
Total Assets 462 55,398 151,699 104,374 162,758
Stock Holders Equity 462 54,372 128,909 83,987 117,048
Total Debt 0 0 0 0 0
Cash flow
C F operating activities 0 (1,824) (44,012) (55,048) (77,203)
C F investing activities 0 1,746 (1,221) (41,531) (63,275)
C F financing activities 0 56,952 129,259 2,215 135,973
FINANCIAL SNAPSHOT (In ‘000 and USD)
1. w/Torisel
2. Single agent/combination
3. w/chemotheraphy
4. w/paclitaxel
5. Combination and Single Agent
6. Single Agent
7. Single Agent
1. Single Agent
2. Combination w/Xeloda
Source: form 10k,2014 pg. no 60
Source: form10k, 2014 pg.no 7
3. PHASE 1 PHASE2 PHASE3 COMPLETION
PIPELINE
5 CATALYST
DRUG INDICATION
Combination w/Torisel
Metastatic Breast
Cancer
Single
agent/combination
Metastatic Breast
Cancer with Brain mets
Combination
w/chemotheraphy
Neoadjuvant Breast
Cancer
Combination
w/paclitaxel
Metastatic Breast
Cancer
Combination and Single
Agent
HER2 Mutated NSCLC
Single Agent
HER2 Mutated Breast
Cancer
Single Agent
HER2 Mutated Solid
Tumors
DRUG INDICATION
Single Agent
Adjuvant Breast
Cancer
Combination
w/Xeloda
Metastatic Breast
Cancer
Source: form10k, 2014 pg.no 7
4. 2007
Formed in April 2007 and was a “shell” company with no specific
business plan or purpose
2010
Sept.: Former Puma was formed
2011
Aug.: License agreement with Pfizer
Oct. : Aquried Former Puma on 4th Oct.
2012
Nov.: Established and incorporated as Puma Biotechnology Ltd.
Source: MANAGEMENT TEAM
COLLABORATION & LICENCE AGREEMENT SHARE HOLDING PATTERN
TEAM MANAGEMENT HISTORY
ABOUT COMPANY
Source: SHAREHOLDINGS
Source: form10K, 2014 pg no 20
NAME QUALIFICATION DESIGNATION
PREVIOUS
DESIGNATION
Alan H. Auerbach
M.S. & B.S
Biomedical
Engineering
CEO, President & Chairman
of the Board
CEO, President
Richard Bryce MBChB, BSc Senior VP Clinical R&D Lead Clinical R&D
Charles R. Eyler M.B.A; B.S
Senior VP Finance and
Administration and
Treasurer
Vice President of
Finance
Erin E. Jones M.S & B.S
VP Global Regulatory
Affairs
COMPANY NAME
MONTH &
YEAR
DESCRIPTION
Pfizer and NSABP 2010
A clinical trials cooperative group
supported by the National Cancer Institute, or
NCI, initiated a study to investigate the use of
neratinib as a neoadjuvant (preoperative)
therapy for newly diagnosed HER2-positive
breast cancer.
Sources: form10k,2014 pg. no.9
5 CATALYST
TOP 5 SHAREHOLDERS
(VALUES IN
PERCENTAGE)
NO. OF SHARES
ADAGE CAPITAL PARTNERS GP LLC 20 5,686,668
FMR LLC 14 4,025,798
PRICE T ROWE ASSOCIATES INC /MD/ 10 2,998,090
CAPITAL RESEARCH GLOBAL INVESTORS 7 2,040,740
VANGUARD GROUP INC 6 1,659,598
OTHERS 44 12,736,611
TOTAL 100 29,147,505
5. 5 CATALYST
Particulars 2010 2011 2012 2013 2014
Revenue 0 0 0 0 0
COGS 0 0 0 0 0
Gross profit/loss 0 0 0 0 0
R&D (15,976) (826) (49,636) (45,046) (22,917)
G&A Exp (9,331) (24,814) (9,787) (19,358)
Operating Loss (15,976) (2,504) (54,820) (47,314) (103,124)
Finance
income(expense)
-76 98 174 310
Net Income/loss (15,976) (2,580) (54,722) (47,140) (102,814)
FINANCIAL STATEMENTS (In ‘000s USD except ratios)
INCOME STATEMENT
Particulars 2010 2011 2012 2013 2014
Current Asset
Total Current Assets 462 53,663 148,972 96,396 149,379
Total assets 462 55,398 151,699 104,374 162,758
Current Liabilities
Total Current Liabilities 587 21,701 19,271 44,441
Long-Term Debt 0 0 0 0
Other Liabilities 0 0 0 0
Deferred Liability 439 1,089 1,116 1,269
Total Liabilities 1,026 22,790 20,387 45,710
Equity 462 54,372 128,909 83,987 117,048
Total Equity and Liability 462 55,398 151,699 104,374 162,758
BALANCE SHEET
Particulars 2010 2011 2012 2013 2014
Net loss (15,976) (10,233) (74,352) (54,659) (141,965)
Liabilities 0 306 9,981 (8,331) 24,792
Net C F Operating 0 (1,824) (44,012) (55,048) (77,203)
Capital expenditures 0 (254) (591) (624) (1,100)
Investments 0 0 0 0
Other investing activities 0 (1,492) (630) (40,907) (62,175)
Net C F Investing 0 (1,746) (1,221) (41,531) (63,275)
Sale and Purchase of Stock 0 56,741 129,214 0 129,440
Net C F Financing 0 56,952 129,259 2,215 135,973
Net cash flow 0 53,382 84,026 (94,364) (4,505)
CASH FLOW STATEMENT
Ratios 2010 2011 2012 2013 2014
ROE -3458% -9.41% -59.71% -44.28% -102.28%
ROCE -3458% -9.13% -59.82% -44.45% -102.59%
ROA -3458% -9.24% -52.85% -36.82% -76.98%
ROIC -521.21% 1457.50% 190.99% 848.30%
EPS (5.33) (0.33) (2.52) (1.64) (3.43)
BVPS 0.154 7.02 5.93 2.93 3.9
RATIOS
Source: form 10k,2014 pg no 60
6. POSITIVE NEWS
10
50
90
130
170
210
250
290
CLOSING PRICE
Upsizing and Pricing of
$120 Million Public
Offering of Common Stock
Agreement with FDA on Special
Protocol Assessment for Phase III
Trial of PB272
Joins the broad-
market Russell
3000® Index
Neratinib graduate from
the I-SPY 2 trial
Amendment to
Neratinib Licensing
Agreement with Pfizer
Expands Cohort in Phase II Trial of
PB272 in HER2 Mutation Positive
Cancer Patients
5 CATALYST
POSITIVE NEWS
